Effect of a selective CYP2C9 inhibitor on the pharmacokinetics of nateglinide in healthy subjects

By Sabia Helene   Sunkara Gangadhar   Ligueros-Saylan Monica   Wang Yibin   Smith Harold   McLeod James   Prasad Pratapa  

European Journal of Clinical Pharmacology, Vol. 60, Iss. 6, 2004-09 ,pp. : 407-412

Springer Publishing Company

Access to resources Recommend Favorite

Influence of Cytochrome P450 (CYP) 3A5 Polymorphisms on the Pharmacokinetics of Lansoprazole Enantiomers in CYP2C19 Extensive Metaboliser Renal Transplant Recipients

By Miura Masatomo  

Clinical Drug Investigation, Vol. 27, Iss. 4, 2007-01 ,pp. : 251-258

Adis International

Access to resources Recommend Favorite

The effect of lansoprazole, an OCT inhibitor, on metformin pharmacokinetics in healthy subjects

By Ding Yi   Jia YanYan   Song Ying   Lu ChengTao   Li YuWen   Chen MinChun   Wang MingMing   Wen AiDong  

European Journal of Clinical Pharmacology, Vol. 70, Iss. 2, 2014-02 ,pp. : 141-146

Springer Publishing Company

Access to resources Recommend Favorite

Pharmacokinetic differences between the enantiomers of lansoprazole and its metabolite, 5-hydroxylansoprazole, in relation to CYP2C19 genotypes

By Miura M.   Tada H.   Yasui-Furukori N.   Uno T.   Sugawara K.   Tateishi T.   Suzuki T.  

European Journal of Clinical Pharmacology, Vol. 60, Iss. 9, 2004-11 ,pp. : 623-628

Springer Publishing Company

Access to resources Recommend Favorite

Effect of moxidectin on CYP3A4 activity as evaluated by oral midazolam pharmacokinetics in healthy subjects

By  

Clinical Pharmacology In Drug Development, Vol. 3, Iss. 2, 2014-03 ,pp. : 151-157

John Wiley & Sons Inc

Access to resources Recommend Favorite